The company has previously announced enrollment of the first patient in a clinical trial (except OA, run by USYD) and I doubt they would miss this opportunity in the first P2 trial funded by them (or us paying shareholders I should say):
GvHD first patientGvHD last patient Cohort AMENDDFUHaving said that, given the recruitment history of the P1 trial, it took almost 11 weeks for the first patient to be enrolled and a further 26 weeks for the remaining 7 patients in Cohort A to be enrolled - none of which were recruited in AU, in fact, not a single patient out of 16 patients has been recruited in AU back then.
However, the P2 trial is recruiting High Risk acute GvHD patients vs Steroid Refractory acute GvHD patients in the P1 trial, which makes the pool of possible patients a lot larger this time around (which is also reflected in the inclusion/exclusion criteria listed). Plus, recruitment now includes two centres in the US already (New York and Chicago).
Anyways, my guess (and that's all it is, a guess) is that we see the first patient coming from the US before end of this calendar year and before management goes into hibernation over Christmas and New Year as usual. Fortunately, no one is expecting any Christmas cards from them this year.
(20min delay)